A renowned University of Arizona pulmonary physician-scientist whose research and clinical interests focus on severe asthma, Monica Kraft, MD, is featured in four articles with videos in MD Magazine and its online presence at mdmag.com related to her participation at the 2018 CHEST Annual Meeting, the yearly conference of the American College of Chest Physicians, in San Antonio, Oct. 6-10.
Dr. Kraft is professor and chair of the UA Department of Medicine, the Robert and Irene Flinn Endowed Chair of Medicine at the UA College of Medicine – Tucson, and deputy director of the UA Health Sciences Asthma and Airway Disease Research Center. She is also a member of the National Institutes of Health’s National Heart, Lung, and Blood Advisory Council and a past president of the American Thoracic Society.
The articles and videos in which Dr. Kraft is featured appear on the magazine’s website on Oct. 8-11 as part of the publication’s CHEST conference coverage. They include:
- Oct. 8, 2018: “Dupilumab's Two-Fold Targeting” | More than a week before the U.S. Food and Drug Administration rules on the supplemental biologics application of dupilumab (Dupixant), what makes the monoclonal antibody so enticing to the asthma community? — https://www.mdmag.com/conference-coverage/chest-2018/monica-kraft-md-dupilumabs-twofold-targeting
- Oct. 9, 2018: “Steps Leading Up to Treating Severe Asthma” | Before biologics are implemented, what should physicians be doing to ensure asthma control in their patients? — https://www.mdmag.com/conference-coverage/chest-2018/monica-kraft-md-steps-leading-up-to-treating-severe-asthma
- Oct. 10, 2018: “Finding, Fighting Comorbidities in Severe Asthma” | Why delving into the symptoms of the most at-need patients is critical for care — https://www.mdmag.com/conference-coverage/chest-2018/monica-kraft-md-finding-fighting-comorbidities-in-severe-asthma
- Oct. 11, 2018: “The New Biologics Entering Asthma” | The 2019 CHEST Meeting in New Orleans may be headlined by newly approved therapies including dupilumab and tezepelumab — https://www.mdmag.com/conference-coverage/chest-2018/monica-kraft-md-the-new-biologics-entering-asthma
You’ll find the related videos posted below:
■ “Fighting Inflammation with Dupilumab”
■ “Treating Severe Asthma, Step by Step”
■ “Finding and Fighting Severe Asthma Comorbidities”
■ “How Biologics Will Highlight Asthma 2019 News”
EXTRA INFO: Dupilumab inhibits overactive signaling of IL-4, IL-13
Regeneron Pharmaceuticals Inc. and Sanofi announced Oct. 19 that the U.S. Food and Drug Administration had approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
“Renowned Asthma Researcher, Dr. Monica Kraft Picked for Prestigious NIH Advisory Post” | Posted Aug. 14, 2018